# Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct06082167/  
OnCo record `nct06082167` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing Zanzalintinib in head and neck squamous cell carcinoma, active and no longer recruiting.

## Summary

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 2/3 interventional study registered as NCT06082167, led by Exelixis with Merck Sharp & Dohme, and active but no longer recruiting on the registry. Official title: A Phase 2/3, Randomised, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Planned enrolment is 600 participants (estimated). The study started in 2024-06-07 and primary completion is expected in 2028-08. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: STELLAR-305
- Tags: ctgov-ingest
- Registry id: NCT06082167
- Phase: 2/3
- Setting: A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Sponsor: Exelixis
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT06082167: https://clinicaltrials.gov/study/NCT06082167

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Recurrent or metastatic head and neck squamous cell carcinoma](https://onco.cc/cancers/recurrent-metastatic-hnscc/)
- drugs: [Zanzalintinib](https://onco.cc/drugs/zanzalintinib/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/)

---
JSON: https://onco.cc/api/v1/entities/nct06082167.json